PI3K-IN-46

CAS No. 304645-61-2

PI3K-IN-46( —— )

Catalog No. M35823 CAS No. 304645-61-2

PI3K-IN-46 is a specific inhibitor of PI3Kγ.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 227 Get Quote
5MG 256 Get Quote
10MG 375 Get Quote
25MG 562 Get Quote
50MG 775 Get Quote
100MG 1042 Get Quote
200MG 1414 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PI3K-IN-46
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K-IN-46 is a specific inhibitor of PI3Kγ.
  • Description
    PI3K-IN-46 (Intermediate 4) is an intermediate in the synthesis of PI3K inhibitor (2-imino-azolinone-vinyl fused-benzene derivative) that can be used for the research of autoimmune disorders, cardiovascular diseases, and neurodegenerative diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    304645-61-2
  • Formula Weight
    255.3
  • Molecular Formula
    C13H9N3OS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C1=CC2=C(C=C1)N=CC=C2)=C3C(=O)N=C(N)S3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rueckle T, et, al. 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors. US8106214B2.
molnova catalog
related products
  • TGR-1202 R-enantiome...

    TGR-1202 R-enantiomer is is the less active enantiomer of TGR-1202 (Umbralisib), TGR-1202 is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.

  • 740 Y-P(TFA)

    740 Y-P(TFA) is a potent and cell-permeable activator of PI3K.740 Y-P is a synthetic biotinylated peptide.

  • BPR1J-097 hydrochlor...

    BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.